About Event
Welcome to the 4th GPCR-Targeted Drug Discovery Summit
As GPCR excitement continues to grow, join your peers for 3 jam-packed days of content spanning from discovery to preclinical and clinical development. Curated with insights from Structure Therapeutics, Novartis, and Tectonic Therapeutics, this GPCR-focussed agenda will cover all things GPCR, from identifying new GPCR targets and understanding MoA to design selective & effective drugs through to streamlining translation to enable better drugs to reach patients faster.
With 3-days of jam-packed content spanning from discovery to pre-clinical and clinical development, expect new data and thought-provoking discussions on hot targets of interest (such as Serotonin receptor agonists and GLP-1), mechanism of action of new GPCR ligands, temporal signaling and translatability into disease modifying drugs that will drive forward your discovery and development pipelines to patients in need.
18+ Expert Speakers will be sharing data and empowering you to:
Leverage machine learning & computational modelling to accurately predict molecular interactions and identify new GPCR targets to improve and accelerate the discovery and development process, with Structure Therapeutics, Aikium and Biagon
Overcome structural biology limitations by understanding structural diversity and mechanism of action to design selective and effective drugs across GPCR subtypes, with Eli Lilly, Tectonic Therapeutic and Confo Therapeutics
Harness the potential of GPCR-targeting drugs for metabolic disorders by identifying new obesity targets beyond GLP-1 to broaden the scope of potential therapeutic interventions and ensure improved outcomes, with Biolexis Therapeutics
Advance your high potential candidates seamlessly through preclinical and clinical development through deep dive case studies from Pathios Therapeutics and OKYO Pharma on successful phase I/II trials of GPCR-targeted drugs
What your peers have to say:
“This meeting brings together major players in the area of discovering novel therapeutics targeting GPCRs providing an opportunity to remain up to date on recent advances in the field and create partnerships.”
Laurent Sabbagh, Scientific Director Biology, Domain Therapeutics
“I am excited to learn from and share expertise with peers across the industry who are united by the common goal of overcoming challenges to deliver life-changing drugs to patients.”
Laetitia Comps-Agrar, Director and Senior Principal Scientist - Biochemical & Cellular Pharmacology, Genentech
“It's always great to be in a group working on a common target class and to hear about how others are pushing the field forward.”
Richard Yu, Co- Founder & Chief Executive Officer, Abalone